

Early and locally advanced breast cancer (update) Committee meeting 10

Date: 9-10 November 2017

Location: RCOG, London

Minutes: Confirmed

| Committee members present: | | |
|-----------------------------------|--|---------------------------------|
| Jane Barrett (Chair) | | (Present for items 1 – 8) |
| Anne Armstrong (Topic Advisor) | | (Present for items 1 – 8) |
| Faye Coe | | (Present for items 1 – 5) |
| Ramsey Cutress | | (Present for items 1 – 8) |
| Carmel Gulliver-Clarke | | (Present for items 1 – 5) |
| Sadaf Haque | | (Present for items 6 – 8) |
| Roger Hunt | | (Present for items 1 – 8) |
| Peter Jenkins | | (Present for items 1 – 8) |
| Imogen Locke | | (Present for items 1 – 8) |
| Marina Parton | | (Present for items 1 – 8) |
| Linda Pepper | | (Present for items 1 – 8) |
| Mia Rosenblatt | | (Present for items 1 – 5) by VC |
| William Teh | | (Present for items 1 – 7) |
| Ursula Van Mann | | (Present for items 1 – 8) |
| Lisa Whisker | | (Present for items 1 – 8) |
| Sairanne Wickers | | (Present for items 1 – 8) |

| In attendance: | | |
|-----------------------|--------------------------------------|-------------------------------|
| Andrew Harding | NICE Guideline Commissioning Manager | (Present for items 6 – 8) |
| Sarah Palombella | NICE Senior Medical Editor | (Present for items 1 – 5) |
| Adam Storrow | NICE Business Analyst | (Present for items 1 – 5) |
| Nathan Bromham | NGA Senior Systematic Reviewer | (Present for items 1 – 8) |
| Hilary Eadon | NGA Guideline Lead | (Present for items 1 – 8) |
| Sally Humphreys | NGA Project Manager | (Present for items 1 – 8) |
| Laura O’Shea | NGA Systematic Reviewer | (Present for items 1 – 8) |
| Anuja Pandey | NGA Systematic Reviewer | (Present for items 1 – 8) |
| Matthew Prettyjohns | NGA Senior Health | (Present for items 3 – 4) (by |

| | | |
|--|-----------|-----|
| | Economist | VC) |
|--|-----------|-----|

| | |
|-------------------------|--------------------------------------|
| Apologies Day 1: | |
| Sadaf Haque | Committee Member |
| Andrew Harding | NICE Guideline Commissioning Manager |
| John Graham | NGA Clinical Advisor |
| Elise Hasler | NGA Information Scientist |
| Apologies Day 2: | |
| Faye Coe | Committee Member |
| Carmel Gulliver-Clarke | Committee Member |
| Mia Rosenblatt | Committee Member |
| Sarah Palombella | NICE Senior Medical Editor |
| Adam Storrow | NICE Business Analyst |
| John Graham | NGA Clinical Advisor |
| Elise Hasler | NGA Information Scientist |
| Matthew Prettyjohns | NGA Senior Health Economist |

| |
|--|
| 1. Welcome and objectives for the meeting |
| <p>The Chair welcomed the Committee members and attendees to the tenth meeting on Early and locally advanced breast cancer.</p> <p>The Chair informed the Committee that apologies had been received. These are noted above.</p> <p>The Chair outlined the objectives of the meeting which included reviewing the evidence and drafting recommendations for questions 8.3, 5.1, 2.2 and 11.1, reviewing the economic model for question 5.1, reviewing the guideline pathway algorithm, considering patient-preference decision points, and considering the recommendations and research recommendations drafted for the whole guideline. In addition, the committee were informed of updated evidence searches, and draft recommendations for the NICE Technology Appraisal of intrabeam.</p> |
| 2. Confirmation of matter under discussion, and declarations of interest |

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Early and locally advanced breast cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

| Name | Job title, organisation | Declarations of Interest, date declared | Type of interest | Decision taken |
|------------------|--|--|---------------------------------|-------------------------|
| Dr Peter Jenkins | Consultant Oncologist, Cheltenham General Hospital | 10.11.2017 Local principal investigator for AFFINITY (A prospective, randomized multicenter, multinational, two-arm comparison of chemotherapy plus trastuzumab given for a total of one year versus chemotherapy plus trastuzumab and pertuzumab given for a total of one year as adjuvant therapy in patients with operable HER2-positive primary breast cancer). Funded by Roche | Non-personal financial specific | Declare and participate |

| | | | | |
|---------------|--|---|-----------------------------|---|
| Marina Parton | Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts | 6.11.2017 Clinical expert on behalf of Eisai for NICE TA on eribulin chemotherapy on 2.11.2017 | Personal financial specific | Withdraw from discussion of any interventions made by Eisai |
|---------------|--|---|-----------------------------|---|

3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

4. Presentations on Day 1

The Chair introduced

The Chair introduced Nathan Bromham, NGA Senior Systematic Reviewer, who gave a presentation on the evidence for Review question 8.3 - Is there a subgroup of people with early invasive breast cancer for whom partial breast radiotherapy is an equally effective alternative to whole breast radiotherapy after breast-conserving surgery?

The Chair introduced Sarah Palombella, NICE Senior Medical Editor, who gave a presentation on the information for the public.

The Chair introduced Laura O'Shea, NGA Systematic Reviewer, who gave a presentation on the evidence for Review question 5.1 - Which people with early and locally advanced breast cancer would benefit from the incorporation of taxanes in adjuvant chemotherapy? The Committee completed a consensus questionnaire on this topic and the results were presented.

The Chair introduced Matthew Prettyjohns, NGA Senior Health Economist, who gave a presentation on the economic model for Review question 5.1 - Which people with early and locally advanced breast cancer would benefit from the incorporation of taxanes in adjuvant chemotherapy?

The Chair introduced Nathan Bromham, NGA Senior Systematic Reviewer, who gave a presentation on the evidence for Review question 2.2 What are the best strategies to prevent lymphoedema following axillary intervention?

The Chair introduced Nathan Bromham, NGA Senior Systematic Reviewer, and Laura O'Shea, NGA Systematic Reviewer, who informed the committee of the

results of the updated evidence searches.

The Chair introduced Hilary Eadon, NGA Guideline Lead, who led a discussion on patient-preference decision points in the guideline.

The speakers took questions from the group. The Committee then discussed the issues presented in relation to this guideline. The Chair thanked the speakers for their presentations.

5. Questions and discussion on Day 1

The Committee discussed the evidence for review questions and agreed recommendations and content for the guideline sections linking the evidence to recommendations.

The Committee discussed the economic evidence for review question 5.1, the results of the model and the recommendations.

The Committee discussed the use of patient-preference decision aids and concluded that they were not suitable for use in this guideline due to the complexity of the issues for each person.

6. Presentations on Day 2

The Chair introduced Anuja Pandey, NGA Systematic Reviewer, who gave a presentation on the evidence for Review question 11.1 - What lifestyle changes improve breast cancer-specific outcomes in people treated for early and locally advanced breast cancer?

The Chair led a review of the pathway algorithm for the guideline.

The Chair led a review of all recommendations developed for the guideline.

7. Questions and discussion on Day 2

The Committee discussed the evidence for the review question and agreed recommendations and content for the guideline sections linking the evidence to recommendations.

The Committee discussed the recommendations developed for the whole guideline and agreed changes to the wording and order.

8. Any other business

The Committee were informed of the draft recommendations for the NICE Technology Appraisal of intrabeam.

The dates for the progress of the guideline were outlined.

Equalities issues:

The Committee highlighted the fact that some treatments are withheld on the basis of age alone and that this is potentially discriminatory as co-morbidities and general fitness are the important factors in determining some treatments.

Date of next meeting: March 2018

Location of next meeting: RCOG, London